News

In a phase Ib study, greater than 90% of prasugrel-treated patients achieved greater than 20% inhibition of platelet aggregation, compared with less than 50% of Plavix treated patients.

Coreg CR is the controlled release formulation of the already marketed Coreg. The new formulation was developed with Flamel Technologies’ micropump technology and is designed to control dissolution

The new process, described in the journal BioTechniques, involves an new method of intravenously injecting DNA into animals, whose immune systems respond by producing antibodies that can be

The company said in a statement that it is undertaking an evaluation of these issues and that significant safety concerns have been identified in the trial to date.

The transaction includes an initial payment of $5 million in cash and the issuance of 11.5 million shares of Pharmos common stock for a combined value of approximately

In November 2002, AdipoGenix and J&J entered a drug discovery collaboration in which AdipoGenix has utilized its proprietary human fat cell based technologies for discovering compounds that reduce

Data showed that treatment with Chrysalin (TP508) in the 503 participants did not relate to a statistically significant benefit compared to placebo in the primary efficacy endpoint, a

Targeted enrollment will be expanded from 74 to 330 patients. The expanded phase II/III trial will include additional study sites outside the US. In order to support the

In May 2002, ActivX and Kyorin entered into a collaboration for the discovery and development of new drugs for the treatment of type 2 diabetes. The companies’ joint